Phosphoproteomic analysis using global mass spectrometry in osimertinib-resistant NSCLC patients identified the activated p21-activated kinase 2 (PAK2)/β-catenin axis as a driver of osimertinib resistance. This evidence concerns the gene PAK2 and non-small cell lung carcinoma.